Table 1.
Demographic and clinical characteristics of the ≥2 AD group, AD group and healthy controls at baseline.
| Treated with ≥2 AD (N = 17) | Treated with 1 AD (N = 32) | HC (N = 19) | Test-statistic | p | ||
|---|---|---|---|---|---|---|
| Age (years) | Mean (SD) | 38.88 (10.13) | 38.81 (11.59) | 39.58 (9.66) | F(2,65) = 0.03 | .97 |
| Sex | Male/Female | 9/8 | 11/21 | 10/9 | X2(2) = 2.33 | .31 |
| Education (years) | Mean (SD) | 11.12 (2.71) | 12.16 (2.93) | 12.32 (2.49) | F(2,65) = 1.03 | .36 |
| Scan location | A/L/G | 5/7/5 | 11/9/12 | 6/7/6 | X2(4) = 0.97 | .91 |
| Illness severity (IDS) baselinea | Mean (SD) | 32.53 (8.26) | 29.42 (9.38) | 4.00 (3.30) | t(44) = 1.01b | .28 |
| Anxiety severity baseline (BAI)a | Mean (SD) | 18.13 (8.77) | 14.94 (8.20) | 1.74 (2.62) | t(44) = 1.21b | .23 |
| Anxiety comorbidity | N (%) | 11 (64.7) | 18 (56.3) | – | X2(1) = 0.33 | .57 |
| Months illness | ||||||
| (in past 5 years) | Mean (SD) | 22.76 (14.16) | 25.03 (16.86) | – | U(47) = 263 | .85 |
| No. of episodes | Mean (SD) | 9.53 (11.47) | 6.19 (8.39) | – | U(47) = 216 | .21 |
| Medication steps | N (1/2/3/4) | 0/14/2/1 | 32/0/0/0 | – | X2(3) = 49.00 | .00 |
| Med use baseline | N (%) | 16 (94.1) | 16 (50.0) | – | X2(1) = 9.54 | .00 |
| Psychotherapy at baseline | Yes/no | 12/5 | 15/17 | – | X2(1) = 2.52 | .11 |
| Psychotherapy during follow-up | Yes/unknown | 16/1 | 18/14 | – | X2(1) = 7.50 | .01 |
HC Healthy Controls, IDS = Inventory of Depressive Symptomatology, FU = Follow-up, BAI = Beck Anxiety Inventory, A = Amsterdam, L = Leiden, G = Groningen.
a
≥2 AD sample N = 15, 1 AD sample N = 31.
b
Test-statistic based on difference between the 1 AD group and the ≥2 AD group.